Compare LITB & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | INKT |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 70.6M |
| IPO Year | 2013 | 2021 |
| Metric | LITB | INKT |
|---|---|---|
| Price | $3.42 | $12.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 11.9K | ★ 30.7K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $6.80 |
| 52 Week High | $4.17 | $76.00 |
| Indicator | LITB | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 73.62 | 60.13 |
| Support Level | $2.41 | $10.79 |
| Resistance Level | $4.17 | $12.40 |
| Average True Range (ATR) | 0.26 | 0.88 |
| MACD | 0.09 | 0.14 |
| Stochastic Oscillator | 87.28 | 82.59 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.